MK-677, also known as Ibutamoren, raises growth hormone and IGF-1 without the need for injections. It is one of the most popular compounds among athletes looking to improve recovery, sleep quality, and body composition. But there is a catch that every user needs to understand: MK-677 raises blood sugar.
The question is not whether MK-677 affects glucose — it does, through ghrelin receptor agonism that amplifies GH pulses and increases hepatic glucose output. The real question is: how much, and what do you do about it? This article gives you a practical monitoring protocol that answers both.
How MK-677 Affects Glucose Metabolism
MK-677 is a ghrelin receptor agonist. Ghrelin is the "hunger hormone," but it also stimulates GH secretion from the pituitary. By amplifying the natural GH pulse, MK-677 increases GH and IGF-1 levels. The metabolic side effect: GH is a counter-regulatory hormone that suppresses glucose uptake in peripheral tissues and increases hepatic glucose production (PubMed: MK-677 and insulin sensitivity).
The result is a state of reduced insulin sensitivity that develops gradually over the first 2-4 weeks of use. Research indicates that roughly 30% of users experience a clinically meaningful rise in fasting glucose — some seeing increases of 10-30 mg/dL. The magnitude depends on dose, individual insulin sensitivity, diet, and whether other metabolic stressors are present.
Fasting Glucose
The Monitoring Protocol
A structured monitoring schedule catches problems early, before they become metabolic disturbances that take months to reverse. Here is the protocol we recommend based on bloodwork data from our users and published research (JCEM: Growth hormone and glucose metabolism):
Baseline (Before Starting)
Before your first dose, establish your metabolic baseline: fasting glucose, HbA1c, fasting insulin, and calculate HOMA-IR. This is your reference point. Without it, you cannot distinguish between MK-677-driven changes and your normal metabolic fluctuations. A baseline HbA1c above 5.4% or fasting glucose above 95 mg/dL suggests pre-existing insulin sensitivity concerns.
Week 2: Early Detection
The earliest glucose changes from MK-677 appear within 7-14 days. Check fasting glucose at home using a glucometer. A rise of more than 10 mg/dL from baseline at this point identifies you as sensitive to the compound's glucose effects. This is the time to start berberine or metformin rather than waiting for full-blown insulin resistance to develop.
Week 4: Full Assessment
At 4 weeks, repeat the full panel: fasting glucose, HbA1c, fasting insulin, and HOMA-IR. The glucose effects of MK-677 are typically fully established by this point. Calculate your HOMA-IR: glucose (mg/dL) x insulin (uIU/mL) / 405. A value above 2.5 indicates insulin resistance. If your HOMA-IR is above 2.5 and glucose is above 100 mg/dL, intervention is needed.
Monthly Maintenance
After the first month, check fasting glucose weekly with a home glucometer and run a full metabolic panel (glucose, HbA1c, insulin) monthly. The goal is to keep fasting glucose below 100 mg/dL and HbA1c below 5.6%. If these targets are maintained with or without intervention, you can continue the compound safely. If values trend upward despite intervention, dose reduction or discontinuation should be considered.
Threshold Values and When to Intervene
Having clear thresholds turns monitoring from anxiety into action. Here are the numbers that matter:
- Fasting glucose > 100 mg/dL: Start intervention (berberine). Repeat glucose in 2 weeks.
- Fasting glucose > 110 mg/dL: Add metformin if not already using, or consider dose reduction.
- HbA1c > 5.6%: Full metabolic review. The damage is cumulative — intervene aggressively.
- HOMA-IR > 2.5: Insulin resistance is established. Intervention is not optional.
HbA1c vs. Fructosamine
The Intervention Ladder
If your glucose markers cross the thresholds above, here is a stepwise approach that allows most users to continue benefiting from MK-677 while managing the metabolic side effects:
Step 1 — Berberine. 500 mg twice daily with meals. Berberine improves insulin sensitivity through AMPK activation. It is often sufficient to manage MK-677-induced insulin resistance in the majority of users. Allow 2 weeks to see the full effect (PubMed: Ibutamoren safety profile).
Step 2 — Metformin. If berberine is not enough, metformin (500-1000 mg/day) is the gold standard. Unlike berberine, metformin reduces hepatic glucose production directly — the same pathway that MK-677 amplifies. This makes it mechanistically ideal for countering ghrelin-receptor-mediated glucose elevation.
Step 3 — Dose reduction. Reducing MK-677 from 25 mg to 12.5 mg often cuts the glucose impact in half while preserving most of the GH pulse amplification. This is a reasonable compromise if berberine or metformin are insufficient.
Step 4 — Discontinuation. If glucose continues to rise despite the above measures, stop the compound. Glucose typically returns to baseline within 1-2 weeks of discontinuation.